Nanolive SA
Nanolive SA is a Swiss company delivering breakthrough label-free live cell imaging and analysis solutions that accelerate research in drug discovery, cell therapy, and biotechnology. Their innovative platforms combine 3D live cell imaging with AI-powered digital assays to provide non-invasive, high-content, multiplexed data on living cells over unlimited time periods. Key products include the 3D Cell Explorer series and AI-driven assays like the Smart Mitochondrial AssayLIVE and LIVE T Cell Assay, enabling detailed insights into cell metabolism, immuno-oncology, and cytotoxicity. With over 300 units installed worldwide, patented technology, and a strong scientific foundation, Nanolive is positioned as a leader in live cell analysis for biotech and pharma markets.
Nanolive SA
Nanolive SA is a Swiss company delivering breakthrough label-free live cell imaging and analysis solutions that accelerate research in drug discovery, cell therapy, and biotechnology. Their innovative platforms combine 3D live cell imaging with AI-powered digital assays to provide non-invasive, high-content, multiplexed data on living cells over unlimited time periods. Key products include the 3D Cell Explorer series and AI-driven assays like the Smart Mitochondrial AssayLIVE and LIVE T Cell Assay, enabling detailed insights into cell metabolism, immuno-oncology, and cytotoxicity. With over 300 units installed worldwide, patented technology, and a strong scientific foundation, Nanolive is positioned as a leader in live cell analysis for biotech and pharma markets.
TL;DR
Headquarters: Tolochenaz, Vaud, Switzerland
Founded: 2013
Core product: Label-free tomographic 3D live-cell imaging (3D Cell Explorer family) with AI-driven digital assays
Installed base: Over 300 units
Recent financing: Series C / Series C-1 (initial close Apr 2022; Sep 20, 2022 listed)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Live-cell imaging and analysis for biomedical research, drug discovery, cell therapy, and biotechnology.
Founded
2013
Industry
Biotechnology Research
Tech Stack
Funding Track Record
20000000
Initial closing of US$20 million reported on April 4, 2022; Series C listed on Sep 20, 2022 in company funding summaries.
Investor Signal
“Participation from institutional investors including Taiwania Capital, Innoviva, and Swisscom Ventures”